Tags : RAP-MD

Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies

Vartika Singh March 7, 2019

Shots: The P-III RAP-MD (01,02,03,04) studies involve assessing of Rapastinel (450mg, 225mg) vs PBO as an adjunctive treatment of MDD The P-III RAP-MD-04 study demonstrated unmet 1EPs & 2EPs. RAP-MD […]readmore

Tags : RAP-MD

Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : RAP-MD

﻿Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Allergan Reports Results of Rapastinel in Four P-III RAP-MD Studies